Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() Global Mycoplasma Testing Market Is Expected To Witness A Healthy Growth Rate Of 11% By 2027Increased research, government funding, biotechnology, pharmaceutical sectors, cell culture contamination concerns, advanced technologies, and increased respiratory tract infections is driving mycoplasma testing market.
Concerns about Mycoplasma contamination in cell culture are increasing. Putting market demand to the test Mycoplasmas routinely contaminate bioprocessing and cell culture fluids. It is commonly known that beginning cell cultures have a 1% contamination rate, but continuing cell cultures have a 15% to 35% contamination rate due to mycoplasma. Mycoplasma contamination can occur as a result of inefficient culture procedures or faulty laboratory equipment. Reusing pipet tips is an example of poor culture technique that might disseminate mycoplasma-infected media into otherwise sterile media. Key Strategies Employed by Companies and laboratories in Mycoplasma Testing market Continuous advancements in mycoplasma detection have enabled market participants to create new, quick, and simple-to-use diagnostics. Such innovations tend to provide manufacturers a competitive advantage, therefore key companies are always focusing on investments for new product development and increasing their geographic reach to reinforce their positions in the rapidly growing Mycoplasma Testing market. Some of the recent developments are listed below-
Competitive Landscape Analysis: Mycoplasma Testing Market Global mycoplasma testing market is marked by the presence of well-established market players such as Thermo Fisher Scientific, Inc. (US); Charles River Laboratories International, Inc. (US); Merck KGaA (Germany); Lonza Group (Switzerland); Explore Detailed Insights on Mycoplasma Testing Market Report @ https://meditechinsights.com/ End
|
|